Regulation of LPS-mediated HMGB1 Release by Poly (ADP-ribose) Polymerase-1

聚 (ADP-核糖) 聚合酶 1 调节 LPS 介导的 HMGB1 释放

基本信息

  • 批准号:
    9066511
  • 负责人:
  • 金额:
    $ 28.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-06-01 至 2018-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): High Mobility Group Box-1 (HMGB1) is a transcription factor-like protein that has recently been characterized as a prototypical Damage -Associated Molecular Pattern molecule (DAMP). HMGB1 is a crucial late-acting mediator of sepsis in patients with sepsis, severe sepsis and septic shock. While much attention has been focused on the function of extracellular HMGB1, the mechanisms of HMGB1 release in sepsis have received little consideration. HMGB1 lacks a secretory signal peptide; therefore, it cannot be secreted via the endoplasmic reticulum-Golgi system. The newly synthesized HMGB1 undergoes extensive post-translational modifications, e.g., acetylation of lysine residues that promote active transport of HMGB1 from the nucleus to the endosomal compartment and prevent its re-entry into the nucleus. Another nuclear protein, which is activated in similar inflammatory conditions, is Poly (ADP-ribose) Polymerase-1(PARP-1). PARP-1 is the most abundant isoform of the PARPenzyme family and its continued activation leads to depletion of its substrate, nicotinamide adenine dinucleotide (NAD+), with consequent depletion of adenosine-5'-triphosphate (ATP), energy failure and cell death. The proposed research plan will define the role of PARP-1 in the modulation of lipopolysaccharide (LPS)-mediated HMGB1 transcription, post-translational modification and secretion. The central hypothesis for this grant application is that PARP-1 is essential for LPS-mediated HMGB1 secretion. In this R01 grant application, we propose a comprehensive approach including in vitro and in vivo studies that will define the role of PARP-1 in modulating LPS-mediated HMGB1 release. In Aim 1, we determine the molecular mechanisms whereby PARP-1 regulates LPS-induced HMGB1 secretion in monocytes. We hypothesize that 1) chemical and genetic PARP-1 inhibition modulates mitogen-activated protein kinase (MAPK) pathway activity; 2) PARP-1 inhibition modulates extracellular signal-regulated kinase (ERK) 1/2-mediated histone acetyl-transferase (HAT) activity of p300 and a closely related protein, cAMP response element-binding protein (CREB)-binding protein (CBP); 3) PARP-1 inhibits LPS-mediated HMGB1 gene transcription. In Specific Aim 2, we will determine if PARP-1 inhibition modulates the nuclear export and delivery of HMGB1 to the endosomal compartment for LPS-mediated secretion in monocytes. Under this aim, we will determine: 1) if LPS-mediated HMGB1 trafficking to the lysosomes requires PARP-1 activity; 2) HMGB1 concentration in the lysosomes with or without PARP-1 inhibition 3) HMGB1 acetylation and its correlation with ADP-ribosylation. To verify the results of our in vitro studies we will tet PARP-1 inhibitors in relevant clinical models of sepsis; therefore, in Aim 3 we will assess the potential role of PARP activation in sepsis using cecal ligation and puncture (CLP) procedure in wild-type and PARP-/- mice. Additional studies will be performed to determine the therapeutic window for use of PARP-1 inhibitors in murine sepsis.
描述(由申请人提供):高迁移率族蛋白-1(HMGB 1)是一种转录因子样蛋白,最近被表征为原型损伤相关分子模式分子(DAMP)。HMGB 1是脓毒症、严重脓毒症和脓毒性休克患者中重要的迟发性脓毒症介质。虽然细胞外HMGB 1的功能已受到广泛关注,但脓毒症中HMGB 1释放的机制却很少受到关注。HMGB 1缺乏分泌信号肽;因此,它不能通过内质网-高尔基体系统分泌。新合成的HMGB 1经历了广泛的翻译后修饰,例如,赖氨酸残基的乙酰化,其促进HMGB 1从细胞核主动转运至内体区室并防止其再进入细胞核。另一种在类似炎症条件下活化的核蛋白是聚(ADP-核糖)聚合酶-1(PARP-1)。PARP-1是PARPenzyme家族中最丰富的同种型,其持续活化导致其底物烟酰胺腺嘌呤二核苷酸(NAD+)耗尽,从而导致腺苷-5 '-三磷酸(ATP)耗尽、能量衰竭和细胞死亡。拟议的研究计划将确定PARP-1在脂多糖(LPS)介导的HMGB 1转录,翻译后修饰和分泌的调节中的作用。这项资助的核心假设是 PARP-1是LPS介导的HMGB 1分泌所必需的。在这个R 01基金申请中,我们提出了一个全面的方法,包括体外和体内研究,将确定PARP-1在调节LPS介导的HMGB 1释放中的作用。在目的1中,我们确定PARP-1调节LPS诱导的单核细胞HMGB 1分泌的分子机制。我们假设:1)化学和遗传性PARP-1抑制调节丝裂原活化蛋白激酶(MAPK)通路活性:2)PARP-1抑制调节细胞外信号调节激酶(ERK)1/2介导的p300和一种密切相关的蛋白质,cAMP反应元件结合蛋白(CREB)结合蛋白(CBP)的组蛋白乙酰转移酶(HAT)活性; 3)PARP-1抑制LPS介导的HMGB 1基因转录。在特定目标2中,我们将确定PARP-1抑制是否调节核输出和HMGB 1向内体隔室的递送,以用于单核细胞中LPS介导的分泌。在此目标下,我们将确定:1)LPS介导的HMGB 1运输至溶酶体是否需要PARP-1活性; 2)在有或无PARP-1抑制的情况下溶酶体中的HMGB 1浓度; 3)HMGB 1乙酰化及其与ADP-核糖基化的相关性。为了验证我们的体外研究结果,我们将在脓毒症的相关临床模型中泰特PARP-1抑制剂;因此,在目标3中,我们将在野生型和PARP-/-小鼠中使用盲肠结扎穿孔(CLP)程序评估PARP激活在脓毒症中的潜在作用。将进行其他研究,以确定在鼠脓毒症中使用PARP-1抑制剂的治疗窗。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Dietary Supplementation With Nonfermentable Fiber Alters the Gut Microbiota and Confers Protection in Murine Models of Sepsis.
  • DOI:
    10.1097/ccm.0000000000002291
  • 发表时间:
    2017-05
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Morowitz MJ;Di Caro V;Pang D;Cummings J;Firek B;Rogers MB;Ranganathan S;Clark RSB;Aneja RK
  • 通讯作者:
    Aneja RK
Dietary Cellulose Supplementation Modulates the Immune Response in a Murine Endotoxemia Model.
饮食中补充纤维素调节鼠内毒素血症模型中的免疫反应。
  • DOI:
    10.1097/shk.0000000000001180
  • 发表时间:
    2019-04
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Di Caro V;Cummings JL;Alcamo AM;Piganelli JD;Clark RSB;Morowitz MJ;Aneja RK
  • 通讯作者:
    Aneja RK
From Phantasmagoria to Reality?
从幻境到现实?
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RAJESH K. ANEJA其他文献

RAJESH K. ANEJA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RAJESH K. ANEJA', 18)}}的其他基金

Targeting Sur1-Trpm4 in sepsis-induced brain injury
靶向 Sur1-Trpm4 治疗脓毒症引起的脑损伤
  • 批准号:
    10193865
  • 财政年份:
    2021
  • 资助金额:
    $ 28.79万
  • 项目类别:
Regulation of LPS-mediated HMGB1 Release by Poly (ADP-ribose) Polymerase-1
聚 (ADP-核糖) 聚合酶 1 调节 LPS 介导的 HMGB1 释放
  • 批准号:
    8852631
  • 财政年份:
    2012
  • 资助金额:
    $ 28.79万
  • 项目类别:
Regulation of LPS-mediated HMGB1 Release by Poly (ADP-ribose) Polymerase-1
聚 (ADP-核糖) 聚合酶 1 调节 LPS 介导的 HMGB1 释放
  • 批准号:
    8468013
  • 财政年份:
    2012
  • 资助金额:
    $ 28.79万
  • 项目类别:
Regulation of LPS-mediated HMGB1 Release by Poly (ADP-ribose) Polymerase-1
聚 (ADP-核糖) 聚合酶 1 调节 LPS 介导的 HMGB1 释放
  • 批准号:
    8293488
  • 财政年份:
    2012
  • 资助金额:
    $ 28.79万
  • 项目类别:
Regulation of LPS-mediated HMGB1 Release by Poly (ADP-ribose) Polymerase-1
聚 (ADP-核糖) 聚合酶 1 调节 LPS 介导的 HMGB1 释放
  • 批准号:
    8669994
  • 财政年份:
    2012
  • 资助金额:
    $ 28.79万
  • 项目类别:
PARP-1 is a Negative Modulator of the Heart Shock Response
PARP-1 是心脏休克反应的负调节剂
  • 批准号:
    7020897
  • 财政年份:
    2006
  • 资助金额:
    $ 28.79万
  • 项目类别:
PARP-1 is a Negative Modulator of the Heart Shock Response
PARP-1 是心脏休克反应的负调节剂
  • 批准号:
    7881755
  • 财政年份:
    2006
  • 资助金额:
    $ 28.79万
  • 项目类别:
PARP-1 is a Negative Modulator of the Heart Shock Response
PARP-1 是心脏休克反应的负调节剂
  • 批准号:
    7256506
  • 财政年份:
    2006
  • 资助金额:
    $ 28.79万
  • 项目类别:
PARP-1 is a Negative Modulator of the Heart Shock Response
PARP-1 是心脏休克反应的负调节剂
  • 批准号:
    7457944
  • 财政年份:
    2006
  • 资助金额:
    $ 28.79万
  • 项目类别:
PARP-1 is a Negative Modulator of the Heart Shock Response
PARP-1 是心脏休克反应的负调节剂
  • 批准号:
    7648257
  • 财政年份:
    2006
  • 资助金额:
    $ 28.79万
  • 项目类别:

相似海外基金

Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
  • 批准号:
    EP/Y000331/1
  • 财政年份:
    2023
  • 资助金额:
    $ 28.79万
  • 项目类别:
    Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
  • 批准号:
    10677295
  • 财政年份:
    2023
  • 资助金额:
    $ 28.79万
  • 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
  • 批准号:
    10635599
  • 财政年份:
    2023
  • 资助金额:
    $ 28.79万
  • 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
  • 批准号:
    10752320
  • 财政年份:
    2023
  • 资助金额:
    $ 28.79万
  • 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
  • 批准号:
    478927
  • 财政年份:
    2023
  • 资助金额:
    $ 28.79万
  • 项目类别:
    Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
  • 批准号:
    10855703
  • 财政年份:
    2023
  • 资助金额:
    $ 28.79万
  • 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
  • 批准号:
    10654210
  • 财政年份:
    2023
  • 资助金额:
    $ 28.79万
  • 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
  • 批准号:
    10733915
  • 财政年份:
    2023
  • 资助金额:
    $ 28.79万
  • 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
  • 批准号:
    10667952
  • 财政年份:
    2023
  • 资助金额:
    $ 28.79万
  • 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
  • 批准号:
    10726986
  • 财政年份:
    2023
  • 资助金额:
    $ 28.79万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了